2018
Three-Month Randomized Clinical Trial of Nasal Calcitonin in Adults with X-linked Hypophosphatemia
Sullivan R, Abraham A, Simpson C, Olear E, Carpenter T, Deng Y, Chen C, Insogna KL. Three-Month Randomized Clinical Trial of Nasal Calcitonin in Adults with X-linked Hypophosphatemia. Calcified Tissue International 2018, 102: 666-670. PMID: 29383408, PMCID: PMC5957766, DOI: 10.1007/s00223-017-0382-0.Peer-Reviewed Original ResearchConceptsLevels of FGF23Nasal salmon calcitoninSalmon calcitoninStudy drugVisit 2Day 2Levels of PTHPrincipal outcome variableTmP/GFRSingle subcutaneous dosePlacebo nasal sprayNasal calcitoninSerum calciumSubcutaneous doseVisit 4Dihydroxyvitamin DSerum phosphorusVisit 3Final doseVisit 1Nasal sprayClinical trialsSerial measurementsDrug doseFGF23 production
2017
Single Dose Of Bisphosphonate To Treat Infantile Hypercalcemia
Patel N, Carpenter T, Genel M. Single Dose Of Bisphosphonate To Treat Infantile Hypercalcemia. AACE Clinical Case Reports 2017, 3: e246-e250. DOI: 10.4158/ep161536.cr.Peer-Reviewed Original ResearchSubcutaneous fat necrosisSingle doseSevere hypercalcemiaDihydroxyvitamin DParathyroid hormonePTH parathyroid hormoneLife-threatening complicationsTreatment of hypercalcemiaLow calcium dietWeeks of lifePosterior upper armPg/mLAggressive hydrationTerm neonatesCalcium dietConfluent plaquesRadiologic findingsFat necrosisTreatment courseTherapeutic coolingSubsequent hypercalcemiaHypercalcemiaInfantile hypercalcemiaCalcium levelsPg/
2015
Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23
Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO. Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 2565-2573. PMID: 25919461, PMCID: PMC4495171, DOI: 10.1210/jc.2015-1551.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDose-Response Relationship, DrugDrug Administration ScheduleFamilial Hypophosphatemic RicketsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGlomerular Filtration RateHumansImmunoglobulin GMaleMiddle AgedPhosphorusRecombinant ProteinsTreatment OutcomeYoung AdultConceptsTmP/GFRSerum PiNormal rangeOpen-label phase 1/2 studyElevated fibroblast growth factor 23Fibroblast growth factor 23Phase 1/2 studyDose-escalation studyGlomerular filtration ratePre-dose levelsGrowth factor 23Favorable safety profileMain outcome measuresProportion of subjectsAcademic medical centerPeak PiSerum inorganic phosphorusPg/mLUrinary calciumDose escalationFactor 23Monthly dosesSerum phosphorusDihydroxyvitamin DSafety profile
2014
Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia
Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, Kawakami T, Ito T, Zhang X, Humphrey J, Insogna KL, Peacock M. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. Journal Of Clinical Investigation 2014, 124: 1587-1597. PMID: 24569459, PMCID: PMC3973088, DOI: 10.1172/jci72829.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCalciumFamilial Hypophosphatemic RicketsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGlomerular Filtration RateHalf-LifeHumansInjections, IntravenousInjections, SubcutaneousKidney TubulesMaleMiddle AgedPhosphatesVitamin DYoung AdultConceptsTmP/GFRSerum PiParathyroid hormonePhosphate reabsorptionXLH patientsRenal tubular thresholdSerum parathyroid hormoneFavorable safety profileElevated serum FGF23Renal phosphate reabsorptionLow serum concentrationsPhosphate-regulating endopeptidaseSerum Pi concentrationFGF23 antibodySerum FGF23Dihydroxyvitamin DSafety profileTubular thresholdSingle doseSerum concentrationsKRN23Mean t1/2Potential treatmentPatientsEffect duration
2012
Chapter 26 Familial Hypophosphatemia and Related Disorders
Holm I, Econs M, Carpenter T. Chapter 26 Familial Hypophosphatemia and Related Disorders. 2012, 699-726. DOI: 10.1016/b978-0-12-382040-2.10026-7.Peer-Reviewed Original ResearchAutosomal dominant hypophosphatemic ricketsTumor-induced osteomalaciaRelated disordersClinical featuresHypophosphatemic ricketsPathophysiology of XLHLong-term morbidityDevelopment of ricketsDegenerative joint diseaseHereditary hypophosphatemic ricketsCommon bone diseaseDominant hypophosphatemic ricketsFGF-23Joint painDental abscessDihydroxyvitamin DAvailable therapiesFamilial hypophosphatemiaHypophosphatemic diseasesDental diseaseJoint diseaseBone diseaseChronic featuresTherapeutic approachesRenal phosphate
2011
Demographic, dietary, and biochemical determinants of vitamin D status in inner-city children
Carpenter TO, Herreros F, Zhang JH, Ellis BK, Simpson C, Torrealba-Fox E, Kim GJ, Savoye M, Held NA, Cole D. Demographic, dietary, and biochemical determinants of vitamin D status in inner-city children. American Journal Of Clinical Nutrition 2011, 95: 137-146. PMID: 22170368, PMCID: PMC3238457, DOI: 10.3945/ajcn.111.018721.Peer-Reviewed Original ResearchConceptsParathyroid hormonePmol/LMinority infantsFormula useMeasurement of PTHSkin typeOlder childrenVitamin D insufficientVitamin D intakeVitamin D statusVitamin D fortificationAlkaline phosphatase activityDietary intake dataInner-city childrenClinical ricketsD intakeD statusSerum calciumDihydroxyvitamin DVitamin DD fortificationBlood samplesIntake dataReference rangeTotal alkaline phosphatase activity
2010
Circulating Levels of Soluble Klotho and FGF23 in X-Linked Hypophosphatemia: Circadian Variance, Effects of Treatment, and Relationship to Parathyroid Status
Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, Olear E, Gundberg CM. Circulating Levels of Soluble Klotho and FGF23 in X-Linked Hypophosphatemia: Circadian Variance, Effects of Treatment, and Relationship to Parathyroid Status. The Journal Of Clinical Endocrinology & Metabolism 2010, 95: e352-e357. PMID: 20685863, PMCID: PMC2968736, DOI: 10.1210/jc.2010-0589.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedBone Density Conservation AgentsCalcitriolChildCircadian RhythmEnzyme-Linked Immunosorbent AssayFamilial Hypophosphatemic RicketsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGenetic Diseases, X-LinkedGlucuronidaseHumansKlotho ProteinsMaleMiddle AgedParathyroid HormonePhosphatesVitamin DConceptsSerum KlothoSerum FGF23Higher klotho levelsHospital research unitRenal phosphate handlingAcademic medical centerEffect of treatmentFibroblast growth factorKlotho levelsPTH secretionMedical therapySoluble KlothoDihydroxyvitamin DFGF23 regulationPhosphate handlingMedical CenterFGF23KlothoXLHCircadian variationGrowth factorPTHAdultsHypophosphatemiaTherapy
2005
Relationships among Vitamin D Levels, Parathyroid Hormone, and Calcium Absorption in Young Adolescents
Abrams SA, Griffin IJ, Hawthorne KM, Gunn SK, Gundberg CM, Carpenter TO. Relationships among Vitamin D Levels, Parathyroid Hormone, and Calcium Absorption in Young Adolescents. The Journal Of Clinical Endocrinology & Metabolism 2005, 90: 5576-5581. PMID: 16076940, PMCID: PMC1283091, DOI: 10.1210/jc.2005-1021.Peer-Reviewed Original ResearchConceptsVitamin D statusCalcium absorptionD statusDihydroxyvitamin DVitamin D insufficiencyVitamin D levelsBone mineral densityCalcium absorption fractionYr of ageEffects of prebioticsD insufficiencySerum PTHPTH secretionD calciumParathyroid hormoneD levelsPediatric dataMineral densityMidpubertal boysYoung adolescentsPTHBone formationWhole bodyHigh rateAdolescents
2003
Chapter 25 Familial Hypophosphatemia and Related Disorders
Holm I, Econs M, Carpenter T. Chapter 25 Familial Hypophosphatemia and Related Disorders. 2003, 603-xvi. DOI: 10.1016/b978-012286551-0/50027-0.Peer-Reviewed Original ResearchAutosomal dominant hypophosphatemic ricketsTumor-induced osteomalaciaRelated disordersHypophosphatemic ricketsPathophysiology of XLHDevelopment of ricketsDegenerative joint diseaseHereditary hypophosphatemic ricketsCommon bone diseaseJoint painDental abscessClinical featuresDihydroxyvitamin DFamilial hypophosphatemiaHypophosphatemic diseasesDental diseaseJoint diseaseBone diseaseRenal phosphateEndopeptidase PHEXShort statureHypophosphatemiaXLHDiseaseRickets
1999
Changes in Bone Turnover in Young Women Consuming Different Levels of Dietary Protein1
Kerstetter J, Mitnick M, Gundberg C, Caseria D, Ellison A, Carpenter T, Insogna K. Changes in Bone Turnover in Young Women Consuming Different Levels of Dietary Protein1. The Journal Of Clinical Endocrinology & Metabolism 1999, 84: 1052-1055. PMID: 10084594, DOI: 10.1210/jcem.84.3.5552.Peer-Reviewed Original ResearchUrinary N-telopeptide excretionBone-specific alkaline phosphataseN-telopeptide excretionUrinary calcium excretionBone turnoverLow-protein dietCalcium excretionUrinary calciumProtein dietBone resorptionDietary proteinYoung womenHealthy young womenNegative calcium balanceLow protein intakeHigh-protein dietAlkaline phosphataseSecondary hyperparathyroidismSerum PTHSerum osteocalcinDihydroxyvitamin DCalcium balanceProtein intakeCompensatory increaseDay 4
1990
Vitamin D metabolism in chronic childhood hypoparathyroidism: Evidence for a direct regulatory effect of calcium
Carpenter T, Insogna K, Boulware S, Mitnick M. Vitamin D metabolism in chronic childhood hypoparathyroidism: Evidence for a direct regulatory effect of calcium. The Journal Of Pediatrics 1990, 116: 252-257. PMID: 2299496, DOI: 10.1016/s0022-3476(05)82883-5.Peer-Reviewed Original Research
1989
Hypercalciuric hypophosphatemic rickets, mineral balance, bone histomorphometry, and therapeutic implications of hypercalciuria.
Chen C, Carpenter T, Steg N, Baron R, Anast C. Hypercalciuric hypophosphatemic rickets, mineral balance, bone histomorphometry, and therapeutic implications of hypercalciuria. Pediatrics 1989, 84: 276-80. PMID: 2787497, DOI: 10.1542/peds.84.2.276.Peer-Reviewed Original ResearchConceptsYears of ageHypophosphatemic ricketsDihydroxyvitamin DVitamin DHigh-dose vitamin DUrinary phosphorus excretionUrinary calcium excretionNormal serum calciumParathyroid hormone concentrationsPhosphorus therapyCalcium excretionSymptomatic nephrolithiasisAppropriate therapySerum calciumAlkaline phosphatase activitySevere ricketsBone histomorphometryHormone concentrationsIntestinal absorptionTherapeutic implicationsCardinal featuresRicketsModest dosageHypercalciuriaHypophosphatemia